DSIP 10 mg

Compound profile

DSIP: compound profile, literature landscape and handling notes

Where DSIP came from

The origin story is unusually well documented and unusually cautionary, and it deserves to anchor any honest description of this compound. The work came out of Swiss physiology in the late 1960s and 1970s, associated principally with Monnier and with Schoenenberger, working on the then-live question of whether sleep is driven by a circulating humoral factor. The experimental design was a cross-circulation one. Delta-wave electroencephalographic activity was produced in donor rabbits by low-frequency electrical stimulation of the thalamus, blood was collected from the cerebral venous circulation of those animals, a dialysate of that blood was transferred into recipient animals, and the recipients were reported to show increased delta-wave activity on their own recordings. Fractionation of the active dialysate over several years led to a nonapeptide, which was characterized and named for the effect the fraction had been selected on.

That is the whole basis of the name. The peptide was not identified by isolating a receptor and finding its ligand, nor by knocking out a gene, nor by tracing a biosynthetic pathway. It was identified as the smallest thing that survived a purification funnel whose readout was an EEG trace in a recipient rabbit. Naming a molecule after the assay it fell out of is a defensible convention when the assay is specific, and a serious problem when it is not. An EEG delta measure in a recipient animal is a low-specificity endpoint: many manipulations move it, and a fraction that moves it has not been shown to move it for the reason the name implies.

The consequence is a fifty-year record of over-interpretation. Once a molecule is called delta sleep-inducing peptide, every subsequent discussion starts from the assumption that inducing delta sleep is what it does, and the burden of proof quietly inverts. A researcher approaching this material now should hold the name at arm's length and treat it as a hypothesis from 1977 that was never confirmed, rather than as a summary of established pharmacology. The catalog in this category contains at least one other compound named for the tissue fraction it came out of rather than for a mechanism, and the pattern of misreading that follows is nearly identical in both cases.

Reading the structure of DSIP

The exact sequence, molecular formula and molecular weight for this listing are printed in the specification table further down this page, taken from the product record rather than restated here. What is worth doing is reading that sequence for what it implies, because DSIP is compositionally unlike most of the short peptides in this catalog and the differences are not cosmetic.

The first thing to notice is charge. The peptide carries carboxylate-bearing side chains, aspartate and glutamate, and essentially no basic side chains: no arginine, no lysine, and no histidine. At neutral pH the molecule is therefore net negative, and its isoelectric point sits well down in the acidic range rather than near or above neutrality. Nearly every other short peptide on this site is the opposite case, a molecule whose charge at working pH is carried by arginine and lysine side chains. That single compositional fact propagates into solubility behavior, ion-exchange behavior, ion-pairing behavior on a reversed-phase column and ionization polarity in a mass spectrometer, and it is the reason DSIP is worth treating as its own analytical problem rather than as one more short peptide.

The second thing to notice is how little structure the backbone can support. The sequence is small, glycine-rich and conformationally permissive. Glycine has no side chain and the widest accessible backbone torsion space of any residue, so a glycine-rich nonapeptide in aqueous solution is a flexible, largely disordered chain rather than a folded object. There is no helix here, no turn locked in by a disulfide, no hydrophobic core. Circular dichroism on such a peptide returns a random-coil trace and tells you almost nothing about identity or integrity, which is worth knowing before anyone proposes CD as a release check.

The third is that the molecule is short, unmodified and unprotected. The published record describes it without a fatty-acid chain, without C-terminal amidation in its parent form, and without non-proteinogenic substitutions. There is nothing in the structure that would resist exopeptidase trimming, which is consistent with reports that the peptide disappears from plasma on a timescale of minutes rather than hours. Modified forms exist in the literature, and this is exactly where the naming problem returns: amidated, phosphorylated and tyrosine-extended variants have all been studied and all have been referred to loosely as DSIP in secondary discussion, even though a modification at the terminus of a nonapeptide is a substantial fraction of the molecule.

The target and the pathway in more detail

This section is short on pathway detail for an honest reason: there is no confirmed target. No DSIP receptor has been cloned, no high-affinity binding site has been reproducibly characterized and assigned, and no orphan receptor has been convincingly deorphanized with this peptide as its ligand. That is a remarkable statement to be able to make about a molecule isolated in the 1970s, and it should be stated plainly and early rather than buried after three paragraphs of proposed mechanisms.

The situation on the biosynthetic side is, if anything, weaker. A peptide hormone or neuropeptide is normally traceable to a precursor protein encoded by an identifiable gene, processed at recognizable dibasic cleavage sites by known convertases. For DSIP that chain of evidence has never been closed. No precursor gene has been confidently assigned, and the nonapeptide sequence does not sit inside a well-characterized prohormone the way the enkephalins sit inside proenkephalin or the melanocortins sit inside proopiomelanocortin. Given how thoroughly mammalian genomes have been sequenced and annotated in the intervening decades, the continued absence of a precursor is not a gap waiting to be filled by more sequencing. It is a substantive reason to be careful about how firmly one asserts that the endogenous molecule exists in the form the 1970s work described.

What the literature offers instead of a receptor is a collection of proposed indirect mechanisms, each associated with a small number of groups. Reported interactions with the hypothalamic-pituitary-adrenal axis appear repeatedly, framed as modulation of corticotropin and corticosteroid measures rather than as receptor occupancy. There are reported effects on thermoregulatory measures in rodents. There are reports positioning the peptide as an antioxidant or membrane-stabilizing agent, which is mechanistically a very different kind of claim and does not require a receptor at all. There is a scattered literature invoking opioid and monoaminergic systems, generally on the basis that an antagonist blunted an effect rather than on the basis of direct binding.

None of these threads has converged. For experimental design the practical implication is that DSIP cannot be used as a selective pharmacological tool, because there is no established target to be selective for. Any effect observed with it requires its own mechanistic controls, established within the study, because there is no accepted receptor-level framework to inherit.

What the published literature on DSIP actually measures

The published DSIP literature is best understood as a body of work with a distinct center of gravity in the 1980s, thinning sharply thereafter, and it divides into four strands that are usually blurred together.

The first strand is sleep electrophysiology, which is the founding claim and the weakest of the four. The reports here are recordings in rabbits, rats, cats and some human sleep-laboratory work, with delta-power or slow-wave measures as the endpoint. What matters is that the results are inconsistent across groups. Some laboratories reported changes in delta measures; several others, working with comparable preparations, did not reproduce them. Later commentary from investigators who worked directly on the problem has been notably skeptical about whether the founding effect is real at all. A reader who encounters the claim that DSIP induces delta sleep should know that this is the contested strand of the literature, not the settled part of it.

The second strand is stress-axis work. Reported changes in corticotropin, corticosteroid and catecholamine measures in rodents appear across a number of small studies, and this strand is somewhat more internally consistent than the sleep strand, though the endpoints are indirect and the group diversity is limited.

The third strand is thermoregulation and circadian measurement: reported effects on body temperature regulation and on the phase or amplitude of rhythms in rodents. This strand is small, and much of it comes from a narrow set of laboratories.

The fourth strand is measurement of endogenous DSIP-like material in tissue and plasma by radioimmunoassay, usually reported as DSIP-like immunoreactivity. This phrase should be read carefully. It denotes whatever a particular antiserum bound in a particular extract, and it is not the same as demonstrating that the nonapeptide is present. Immunoreactivity studies were a substantial fraction of the 1980s output and are frequently cited in secondary sources as though they had confirmed the peptide's endogenous existence and regulation. They did not; they measured cross-reactive material.

Across all four strands the methodological era is the limiting factor. These are small studies, mostly predating modern standards for statistical power, preregistration and mass-spectrometric confirmation of peptide identity, and very few have been repeated with contemporary methods.

Where the DSIP literature is thin or frequently misread

This is the section that matters most for DSIP, and it can be stated bluntly.

There is no receptor. Fifty years after isolation, no DSIP receptor has been cloned or convincingly identified. Every mechanistic account in circulation is therefore an inference from a downstream measure, not a description of a ligand-target interaction.

There is no confirmed gene. No precursor has been securely mapped, which is extraordinary for a peptide isolated that long ago and is a legitimate reason for skepticism about whether the endogenous molecule exists as originally described. A peptide with no receptor and no precursor is not a characterized signaling molecule; it is a synthetic nonapeptide with an interesting history.

The founding result has not held up cleanly. Several groups failed to reproduce the sleep-EEG findings, and the modern position of investigators closest to the original work has been openly doubtful. Presenting the sleep effect as established, which most secondary writing does, misrepresents the record.

The name is doing argumentative work it has not earned. Assay-context naming creates an expectation in every reader before they have seen any data, and it has driven fifty years of confirmatory reading. This is the same failure mode as compounds named for the tissue fraction they were purified from.

The provenance of circulating claims is shallow. Most of what is asserted about DSIP online traces to a small 1980s literature, to reviews of that literature, or to material with no primary source at all, rather than to modern controlled work. Following a claim back two or three citation steps very often terminates in a 1980s abstract or a review citing a review.

Finally, the label is used loosely. The string DSIP is applied in secondary sources to the parent nonapeptide and to modified analogs, including amidated and tyrosine-extended forms, without distinguishing them. Those are different molecules with different properties, and data generated on one does not characterize another. Establishing which molecule a given lot actually contains is an analytical question, answered by the documentation for that lot rather than by the name on it.

How DSIP behaves in solution

DSIP is supplied as lyophilized material and its solution behavior is governed by its acidic character, which makes it genuinely different from the basic peptides that dominate this catalog.

The important practical fact is that solubility is pH-dependent and passes through a minimum near the isoelectric point, which for this peptide sits low, in the acidic range rather than near neutrality. At the pI the molecule carries no net charge, electrostatic repulsion between molecules is at its weakest, and the tendency to associate and come out of solution is at its greatest. This produces a bench observation that surprises people used to basic peptides: adding acid does not help here. Acidifying a solution of an arginine-rich peptide generally improves solubility by protonating side chains and increasing net positive charge, and that reflex, applied to DSIP, drives the solution toward its worst region. A neutral to slightly alkaline aqueous environment keeps the carboxylates deprotonated and the molecule charged, which is where it is most comfortable. Anyone working near a low-pH buffer should expect haze or a slow-forming precipitate rather than assume the material was defective.

Ionic strength interacts with this. A charged, hydrophilic, low-molecular-weight peptide is generally salted in at modest ionic strength, but high salt near the pI is where aggregation appears fastest.

Beyond pH, the standard short-peptide liabilities apply and one specific chemical liability is worth checking against the printed sequence. Where an aspartate residue is followed by a small residue such as glycine, serine or alanine, the classic degradation route is intramolecular attack forming a succinimide intermediate that opens to give isoaspartate, producing a species with the same nominal mass and a slightly different retention time. Where an asparagine is present in a similar context, deamidation adds a small mass increment. Both are accelerated by alkaline pH and by warm storage in solution, which sets up a genuine tension with the solubility argument above and is a reason to keep working solutions cold and short-lived rather than merely well buffered. If the printed sequence includes an aromatic residue, that position is the oxidation- and light-sensitive one, and amber vials and minimized headspace are reasonable precautions. Freeze-thaw cycling should be minimized as a matter of course; aliquot once rather than returning repeatedly to a stock. The storage statement in the specification table is the product record for this material and should be read as the manufacturer statement it is.

Analytical notes specific to DSIP

The acidic composition changes the analytical approach in ways that are worth spelling out, because advice written for basic peptides transfers badly here.

Start with detection. Quantitative work on short peptides is normally done at 214 nm, where the amide bond absorbs, and that remains the workhorse wavelength for this material. The usual caveat applies with extra force: a purity figure reported as area percent at 214 nm counts only what absorbs at that wavelength, so every peptide-bond-containing fragment is weighed while residual salts, scavengers and counter-ions largely are not, and the number is systematically flattered. Whether a second, longer wavelength is worth configuring depends entirely on whether the printed sequence contains an aromatic residue. If it does, running 214 nm and 280 nm together is a cheap orthogonal check, because the ratio between the two channels across a peak is an identity signal in itself. If it does not, 280 nm is dead space.

Then ionization polarity, the strong recommendation here and an unusual one for a peptide catalog. Positive-mode electrospray works well for basic peptides because arginine and lysine side chains are readily protonated and hand you a clean multiply charged series. A peptide with no basic side chains has only the N-terminal amine available, so positive-mode signal is weak, the charge envelope is shallow, and sodium and potassium adducts compete for what signal there is. Negative-ion mode suits this molecule far better: the carboxylates deprotonate readily and the deprotonated species is usually the stronger and cleaner ion. A disappointing positive-mode spectrum here is a reason to switch polarity, not a conclusion about the sample.

Chromatography differs too. A small, glycine-rich, hydrophilic peptide is poorly retained on C18 and can elute near the void volume on a gradient built for larger hydrophobic analytes, where no impurity separation is possible. Trifluoroacetic acid as an ion-pairing additive works by pairing with positive charges, so its retention-enhancing effect on a peptide with no basic residues is limited compared with what it achieves on an arginine-rich sequence. A polar-endcapped or aqueous-compatible reversed-phase column run from a very low organic starting point, or a hydrophilic interaction separation, is the more productive direction. On ion exchange the polarity inverts as well: this peptide binds an anion exchanger at neutral pH where most peptides in this catalog would bind a cation exchanger, which is useful preparatively and as a quick orthogonal identity argument.

Compounds researchers confuse with DSIP

Questions specific to DSIP